Yixin Tang Pharmaceutical Group Co., Ltd. (hereinafter referred to as "the Company") held the 2024 Annual Shareholders' Meeting on May 21, 2025, where it approved the proposal on the use of part of the temporarily idle self-owned funds for cash management. The Company and its wholly-owned subsidiaries are authorized to use up to RMB 2.5 billion of idle self-owned funds for cash management (including but not limited to purchasing fixed-income or principal-protected floating-income financial products with a maturity of less than one year, large certificates of deposit, time deposits, notice deposits, and agreed deposits). The cash management amount at any point during the investment period (including the reinvestment of returns from the aforementioned investments) shall not exceed RMB 2.5 billion. Within this limit, funds can be used on a rolling basis, and the Chairman is authorized to handle the implementation of related matters.
1. Cash Management Recovery Situation
According to the resolution of the 2024 Annual Shareholders' Meeting, the Company signed contracts with relevant banks to use part of the temporarily idle self-owned funds for cash management. Some products have matured and the basic situation is as follows: